secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2022-06-29T23:59:59+00:00
Accession:  0001558370-22-010401
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma appoints Vivian Liu to board of directors effective July 1, 2022
-------------------------------------------------------------------------------

- Vivian Liu appointed to Aytu's board as independent director and member of Nominating & Corporate Governance Committee.
- Liu receives initial grant of 6,500 restricted shares; one-third vests July 1, 2023, remainder over eight quarters.
- Liu previously served as President/CEO/CFO of Innovus Pharmaceuticals (acquired by Aytu in Feb 2020) and other biopharma firms.
- CEO Josh Disbrow highlights Liu's clinical and corporate development expertise to support company's growth strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837022010401/0001558370-22-010401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837022010401/aytu-20220624x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-010401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer